TY - JOUR AU - Biró, Orsolya AU - Alasztics, Bálint AU - Molvarec, Attila AU - Joó, József Gábor AU - Nagy, Bálint AU - Rigó, János TI - Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 10 PY - 2017 SP - 207 EP - 212 PG - 6 SN - 2210-7789 DO - 10.1016/j.preghy.2017.09.002 UR - https://m2.mtmt.hu/api/publication/3273020 ID - 3273020 AB - Introduction: Hypertension is a common complication during pregnancy, affecting 10% of pregnant women worldwide. Several microRNA (miRNA) were shown to be involved in hypertensive disorders of pregnancy. In preeclampsia (PE), placental dysfunction causes the enhanced release of extracellular vesicle-derived miRNAs. The hypoxia-sensitive hsa-mir-210 is the most common PE-associated miRNA, but its exosomal profile has not been investigated. Objectives: Our aims were to measure exosomal total-miRNA concentration and to perform expression analysis of circulating exosomal hsa-miR-210 in women affected by chronic hypertension (CHT) gestational hypertension (GHT) or PE. Materials and methods: We collected plasma samples from women with CHT, GHT, PE (moderate: mPE and severe: sPE) and from normotensive pregnancies. Exosomal miRNAs were extracted and miRNA concentration was measured. RT-PCR was carried out with hsa-miR-210-3p-specific primers and relative expression was calculated using the comparative Ct method. Results: The total-miRNA concentration was different in the disease subgroups, and was significantly higher in mPE and sPE compared to the other groups. We found a significant difference in the relative exosomal hsa-miR-210-3p expression between all hypertensive groups compared to the normotensive samples, but significant upregulation was only observed in case of mPE and sPE patients. Both the level of total-miRNA and hsa-miR-210 expression was higher in case of severe PE. Conclusions: The level of circulating exosomal total-miRNA and hsa-miR-210 was elevated in women with PE, and it was higher in the severe form. We showed that hsa-miR-210 is secreted via exosomes, which may have a role in the pathomechanism of the disease. © 2017 International Society for the Study of Hypertension in Pregnancy. LA - English DB - MTMT ER - TY - JOUR AU - Joó, József Gábor AU - Rigó, János AU - Börzsönyi, Balázs AU - Demendi, Csaba AU - Kornya, László TI - Placental gene expression of the placental growth factor (PlGF) in intrauterine growth restriction JF - JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE J2 - J MATERN-FETAL NEO M VL - 30 PY - 2017 IS - 12 SP - 1471 EP - 1475 PG - 5 SN - 1476-7058 DO - 10.1080/14767058.2016.1219993 UR - https://m2.mtmt.hu/api/publication/3098328 ID - 3098328 N1 - First Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary Second Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary Szent István and Szent László Hospitals Budapest, Budapest, Hungary Cited By :8 Export Date: 20 November 2023 CODEN: JMNMA Correspondence Address: Joó, J.G.; Semmelweis University, Baross utca 27, Hungary; email: joogabor@hotmail.com Chemicals/CAS: Biomarkers; PGF protein, human; Placenta Growth Factor LA - English DB - MTMT ER - TY - JOUR AU - Yanez-Mo, M AU - Siljander, PR AU - Andreu, Z AU - Zavec, AB AU - Borras, FE AU - Buzás, Edit Irén AU - Buzás, Krisztina AU - Casal, E AU - Cappello, F AU - Carvalho, J AU - Colas, E AU - Cordeiro-da Silva, A AU - Fais, S AU - Falcon-Perez, JM AU - Ghobrial, IM AU - Giebel, B AU - Gimona, M AU - Graner, M AU - Gursel, I AU - Gursel, M AU - Heegaard, NH AU - Hendrix, A AU - Kierulf, P AU - Kokubun, K AU - Kosanovic, M AU - Kralj-Iglic, V AU - Kramer-Albers, EM AU - Laitinen, S AU - Lasser, C AU - Lener, T AU - Ligeti, Erzsébet AU - Line, A AU - Lipps, G AU - Llorente, A AU - Lotvall, J AU - Mancek-Keber, M AU - Marcilla, A AU - Mittelbrunn, M AU - Nazarenko, I AU - Nolte-'t, Hoen EN AU - Nyman, TA AU - O'Driscoll, L AU - Olivan, M AU - Oliveira, C AU - Pállinger, Éva AU - Del Portillo, HA AU - Reventos, J AU - Rigau, M AU - Rohde, E AU - Sammar, M AU - Sanchez-Madrid, F AU - Santarem, N AU - Schallmoser, K AU - Ostenfeld, MS AU - Stoorvogel, W AU - Stukelj, R AU - Van, der Grein SG AU - Vasconcelos, MH AU - Wauben, MH AU - De Wever, O TI - Biological properties of extracellular vesicles and their physiological functions JF - JOURNAL OF EXTRACELLULAR VESICLES J2 - J EXTRACELLULAR VESICL VL - 4 PY - 2015 PG - 60 SN - 2001-3078 DO - 10.3402/jev.v4.27066 UR - https://m2.mtmt.hu/api/publication/2930099 ID - 2930099 N1 - Yanez-Mo M and Siljander PR authors have contributed equally. The rest of the authors are listed in alphabetical order. Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :955 Export Date: 30 August 2019 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :1100 Export Date: 14 January 2020 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Funding Agency and Grant Number: European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD) [BM1202]; ICREAICREA Funding text: The authors wish to thank Dr R Simpson and Dr D Taylor for critical reading of the manuscript and acknowledge the Horizon 2020 European Cooperation in Science and Technology programme and its support of our European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD; BM1202 www.cost.eu/COST_Actions/bmbs/Actions/BM1202) Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :1581 Export Date: 13 January 2021 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Funding Agency and Grant Number: European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD) [BM1202]; ICREAICREA Funding Source: Custom Funding text: The authors wish to thank Dr R Simpson and Dr D Taylor for critical reading of the manuscript and acknowledge the Horizon 2020 European Cooperation in Science and Technology programme and its support of our European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD; BM1202 www.cost.eu/COST_Actions/bmbs/Actions/BM1202) AB - In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. While intensive investigation has targeted the role of EVs in different pathological processes, for example, in cancer and autoimmune diseases, the EV-mediated maintenance of homeostasis and the regulation of physiological functions have remained less explored. Here, we provide a comprehensive overview of the current understanding of the physiological roles of EVs, which has been written by crowd-sourcing, drawing on the unique EV expertise of academia-based scientists, clinicians and industry based in 27 European countries, the United States and Australia. This review is intended to be of relevance to both researchers already working on EV biology and to newcomers who will encounter this universal cell biological system. Therefore, here we address the molecular contents and functions of EVs in various tissues and body fluids from cell systems to organs. We also review the physiological mechanisms of EVs in bacteria, lower eukaryotes and plants to highlight the functional uniformity of this emerging communication system. LA - English DB - MTMT ER - TY - JOUR AU - Witwer, KW AU - Buzás, Edit Irén AU - Bemis, LT AU - Bora, A AU - Lasser, C AU - Lotvall, J AU - Nolte-'t, Hoen EN AU - Piper, MG AU - Sivaraman, S AU - Skog, J AU - Thery, C AU - Wauben, MH AU - Hochberg, F TI - Standardization of sample collection, isolation and analysis methods in extracellular vesicle research JF - JOURNAL OF EXTRACELLULAR VESICLES J2 - J EXTRACELLULAR VESICL VL - 2 PY - 2013 PG - 25 SN - 2001-3078 DO - 10.3402/jev.v2i0.20360 UR - https://m2.mtmt.hu/api/publication/2471567 ID - 2471567 N1 - Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Department of Biomedical Sciences, University of Minnesota Medical School Duluth, Duluth, MN, United States Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States Massachusetts General Hospital Cancer Center, Boston, MA, United States Exosome Diagnostics, Inc., New York, United States INSERM, Cedex, Paris, France Institut Curie, Paris, France Cited By :807 Export Date: 5 August 2019 Correspondence Address: Witwer, K.W.733 N. Broadway, Miller Research Building, Baltimore, MD 21205, United States; email: kwitwer1@jhmi.edu Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Department of Biomedical Sciences, University of Minnesota Medical School Duluth, Duluth, MN, United States Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States Massachusetts General Hospital Cancer Center, Boston, MA, United States Exosome Diagnostics, Inc., New York, United States INSERM, Cedex, Paris, France Institut Curie, Paris, France Cited By :807 Export Date: 7 August 2019 Correspondence Address: Witwer, K.W.733 N. Broadway, Miller Research Building, Baltimore, MD 21205, United States; email: kwitwer1@jhmi.edu AB - The emergence of publications on extracellular RNA (exRNA) and extracellular vesicles (EV) has highlighted the potential of these molecules and vehicles as biomarkers of disease and therapeutic targets. These findings have created a paradigm shift, most prominently in the field of oncology, prompting expanded interest in the field and dedication of funds for EV research. At the same time, understanding of EV subtypes, biogenesis, cargo and mechanisms of shuttling remains incomplete. The techniques that can be harnessed to address the many gaps in our current knowledge were the subject of a special workshop of the International Society for Extracellular Vesicles (ISEV) in New York City in October 2012. As part of the "ISEV Research Seminar: Analysis and Function of RNA in Extracellular Vesicles (evRNA)", 6 round-table discussions were held to provide an evidence-based framework for isolation and analysis of EV, purification and analysis of associated RNA molecules, and molecular engineering of EV for therapeutic intervention. This article arises from the discussion of EV isolation and analysis at that meeting. The conclusions of the round table are supplemented with a review of published materials and our experience. Controversies and outstanding questions are identified that may inform future research and funding priorities. While we emphasize the need for standardization of specimen handling, appropriate normative controls, and isolation and analysis techniques to facilitate comparison of results, we also recognize that continual development and evaluation of techniques will be necessary as new knowledge is amassed. On many points, consensus has not yet been achieved and must be built through the reporting of well-controlled experiments. LA - English DB - MTMT ER - TY - JOUR AU - Than, Nándor Gábor AU - Romero, R AU - Goodman, M AU - Weckle, A AU - Xing, J AU - Dong, Z AU - Xu, Y AU - Targuini, F AU - Szilágyi, András AU - Gál, Péter AU - Hou, Z AU - Tarca, AL AU - Kim, CJ AU - Kim, JS AU - Haidarian, S AU - Uddin, M AU - Bohn, H AU - Benirschke, K AU - Santolaya-Forgas, J AU - Grossman, LI AU - Erez, O AU - Hassan, SS AU - Závodszky, Péter AU - Papp, Zoltán AU - Wildman, DE TI - A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death JF - PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA J2 - P NATL ACAD SCI USA VL - 106 PY - 2009 IS - 24 SP - 9731 EP - 9736 PG - 6 SN - 0027-8424 DO - 10.1073/pnas.0903568106 UR - https://m2.mtmt.hu/api/publication/1247740 ID - 1247740 N1 - Megjegyzés-23078831 N1 Molecular Sequence Numbers: GENBANK: BK006815, BK006816, BK006817, BK006818, BK006819; Megjegyzés-23078956 N1 Molecular Sequence Numbers: GENBANK: BK006815, BK006816, BK006817, BK006818, BK006819; Megjegyzés-23448845 Megjegyzés-21048538 FU: Perinatology Research Branch, Division of Intramural Research, Eunice : Kennedy Shriver National Institute of Child Health and Human : Development,National Institutes of Health, Department of Health and : Human Services ; National Science Foundation [BCS-0751508, : BCS-0550209]; Hungarian Scientific Research Fund [NK77978, PD73096] FX: We thank Dr. Prasenjit Das, Sivasakthy Sivalogan, and Hong Meng for : assistance; Dr. Sue Land (Wayne State University, Applied Genomic : Technology Center) for running qRT-PCR; Drs. Howard Petty, Sally : Madsen- Bouterse, Maik Huttemann, and Raghavendra Navath for helpful : advice; and Sara Tipton for critically reading the manuscript. We also : thank Drs. Caro-Beth Stewart (State University of New York, Albany, NY) : and Kathy Neiswanger (University of Pittsburgh, Pittsburgh, PA), the : New England Regional Primate Center (Southborough, MA), and the Duke : University Primate Center (Durham, NC) for providing DNA and/or tissue : samples. This research was supported by the Perinatology Research : Branch, Division of Intramural Research, Eunice Kennedy Shriver : National Institute of Child Health and Human Development, National : Institutes of Health, Department of Health and Human Services; by : National Science Foundation Grants BCS-0751508 (to D.E.W.) and : BCS-0550209 (to M. G.); and by the Hungarian Scientific Research Fund : (OTKA) Grants NK77978 (to P.Z.) and PD73096 (to A.Sz.). Megjegyzés-23586307 N1 Molecular Sequence Numbers: GENBANK: BK006815, BK006816, BK006817, BK006818, BK006819; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Detroit, MI 48201, United States Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, United States Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI 48201, United States Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, MI 48201, United States Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, United States Institute of Enzymology, Hungarian Academy of Sciences, H-1113 Budapest, Hungary Behringwerke AG, D-35041 Marburg/Lahn, Germany Department of Pathology, University of California, San Diego, CA 92103, United States Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States First Department of Obstetrics and Gynecology, Semmelweis University, H-1088 Budapest, Hungary Cited By :120 Export Date: 24 October 2019 CODEN: PNASA Correspondence Address: Romero, R.; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Detroit, MI 48201, United States; email: prbchiefstaff@med.wayne.edu AB - Galectins are proteins that regulate immune responses through the recognition of cell-surface glycans. We present evidence that 16 human galectin genes are expressed at the maternal-fetal interface and demonstrate that a cluster of 5 galectin genes on human chromosome 19 emerged during primate evolution as a result of duplication and rearrangement of genes and pseudogenes via a birth and death process primarily mediated by transposable long interspersed nuclear elements (LINEs). Genes in the cluster are found only in anthropoids, a group of primate species that differ from their strepsirrhine counterparts by having relatively large brains and long gestations. Three of the human cluster genes (LGALS13, -14, and -16) were found to be placenta-specific. Homology modeling revealed conserved three-dimensional structures of galectins in the human cluster; however, analyses of 24 newly derived and 69 publicly available sequences in 10 anthropoid species indicate functional diversification by evidence of positive selection and amino acid replacements in carbohydrate-recognition domains. Moreover, we demonstrate altered sugar-binding capacities of 6 recombinant galectins in the cluster. We show that human placenta-specific galectins are predominantly expressed by the syncytiotrophoblast, a primary site of metabolic exchange where, early during pregnancy, the fetus comes in contact with immune cells circulating in maternal blood. Because ex vivo functional assays demonstrate that placenta-specific galectins induce the apoptosis of T lymphocytes, we propose that these galectins reduce the danger of maternal immune attacks on the fetal semiallograft, presumably conferring additional immune tolerance mechanisms and in turn sustaining hemochorial placentation during the long gestation of anthropoid primates. LA - English DB - MTMT ER - TY - JOUR AU - Nyitrayné Pap, Erna AU - Pállinger, Éva AU - Falus, András AU - Kiss, AA AU - Kittel, Ágnes AU - Kovacs, P AU - Buzás, Edit Irén TI - T Lymphocytes are Targets for Platelet- and Trophoblast-Derived Microvesicles During Pregnancy JF - PLACENTA J2 - PLACENTA VL - 29 PY - 2008 IS - 9 SP - 826 EP - 832 PG - 7 SN - 0143-4004 DO - 10.1016/j.placenta.2008.06.006 UR - https://m2.mtmt.hu/api/publication/109957 ID - 109957 N1 - Megjegyzés-21253630 PubMed ID: 18684502 Chemicals/CAS: P-Selectin; Platelet Glycoprotein GPIb-IX Complex AB - Microvesicles (MVs) can derive from several cell types and their membranes contain cell surface elements. Their role is increasingly recognized in cell-to-cell communication, as they act as both paracrine and remote messengers, occurring in circulating form as well as in plasma. Successful pregnancy requires a series of interactions between the maternal immune system and the implanted fetus, such that the semi-allograft will not be rejected. These interactions occur at the materno-placental interface and/or at a systemic level. In the present study we identified for the first time the in vivo plasma pattern of the MVs of third-trimester, healthy pregnant women, their cellular origin, and their target cells using flow cytometry and confocal laser microscopy. We searched for the cellular target molecules of thrombocyte-derived MVs with the help of neutralizing antibodies. We examined the in vitro effects of MVs on STAT3 phosphorylation of primary lymphocytes and Jurkat cells. We found that both placental trophoblast-derived and maternal thrombocyte-derived MVs bind to circulating peripheral T lymphocytes, but not to B lymphocytes or NK cells. We were able to show that the P-selectin (CD62P)-PSGL-1 (CD162) interaction is one mechanism binding platelet-derived MVs to T cells. We were also able to demonstrate that MV-lymphocyte interactions induce STAT3 phosphorylation in T cells. Our findings indicate that both thrombocyte- and trophoblast-derived MVs may play an important role in the immunomodulation of pregnancy. We suggest that the transfer of different signals via MVs represents a novel form of communication between the placenta and the maternal immune system, and that MVs contribute to the establishment of stable immune tolerance to the semi-allograft fetus. LA - English DB - MTMT ER -